Abstract Library

#1396 3-Drugs Chemotherapy Regimen for G3 PanNENs with Ki67 below 55%: Single Institution Experience

Introduction: To date no standard regimen of chemotherapy (CTH) is universally approved for advanced pancreatic neuroendocrine neoplasms (PanNENs) with Ki67<55% and no predictive selection criteria is available.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Grego E

Authors: Grego E, Cingarlini S, Ortolani S, Crosara S, De Robertis R,

Keywords: 3-drugs chemotherapy regimen, pancreatic nets, ki-67% <55%,

#1383 [18F]FDG-PET/CT Heterogeneity in Patients with Metastatic, Well-Differentiated Pancreatic Neuroendocrine Tumours

Introduction: 18F-FDG-PET/CT (FP) often shows an heterogeneous pattern of positivity in patients (P) with pancreatic neuroendocrine tumours (PanNETs).

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Ortolani S

Authors: Ortolani S, Cingarlini S, Citton E, Crosara S, De Robertis R,

Keywords: 18F-FDG-PET/CT, heterogeneity, pancreatic NETs,

#1381 [18F]FDG-PET/CT as a Predictive Tool for Response to Chemotherapy and Everolimus Treatment in Patientes with Pancreatic Neuroendocrine Tumour

Introduction: The predictive role of 18F-FDG-PET/CT (FP) in neuroendocrine tumours is debated.

Conference: 13th Annual ENETSConcerence (2016)

Presenting Author: Ortolani S

Authors: Ortolani S, Cingarlini S, Citton E, Crosara S, De Robertis R,

Keywords: 18F-FDG-PET/CT, predictive, chemotherapy, everolimus, pancreatic NETs,

#1210 Perfusion Changes in Liver Metastases (LM) from Pancreatic Neuroendocrine Tumors (PanNETs) during Everolimus (E) Treatment: Update of Perfusion CT (P-CT) Study.

Introduction: P-CT can evaluate inner perfusional features of primary and metastatic PanNETs; preliminary evidences suggest its potential role in predicting early response to anti-angiogenic therapies. Perfusional modifications induced by E in LM are not completely understood.

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author: De Robertis R

Authors: Ortolani S, De Robertis R, D'Onofrio M, Cingarlini S, Crosara S,

Keywords: perfusion CT, pancreas neuroendocrine tumor, everolimus,

#999 Tumor Perfusion Changes During Everolimus (E) Treatment: Preliminary Results from Perfusion-CT (P-CT) Study

Introduction: Criteria other than RECIST are not validated for evaluation of response during treatment in pancreatic neuroendocrine tumors (pNETs). Preliminary evidence favors antiangiogenic properties of E.

Conference: 11th Annual ENETSConcerence (2014)

Presenting Author: Cingarlini S

Authors: Ortolani S, De Robertis R, Cingarlini S, D'Onofrio M, Crosara S,

Keywords: everolimus, pNET, P-CT,